Inhibition of DNA Glycosylases via Small Molecule Purine Analogs

Aaron C. Jacobs¹, Marcus J. Calkins¹, Ajit Jadhav², Dorjbal Dorjsuren², David Maloney², Anton Simeonov², Pawel Jaruga³, Miral Dizdaroglu³, Amanda K. McCullough¹,4, R. Stephen Lloyd¹,4*

¹Center for Research on Occupational and Environmental Toxicology, Oregon Health and Science University, Portland, Oregon, United States of America, ²National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America, ³Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, Maryland, United States of America, ⁴Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, United States of America

Abstract
Following the formation of oxidatively-induced DNA damage, several DNA glycosylases are required to initiate repair of the base lesions that are formed. Recently, NEIL1 and other DNA glycosylases, including OGG1 and NTH1 were identified as potential targets in combination chemotherapeutic strategies. The potential therapeutic benefit for the inhibition of DNA glycosylases was validated by demonstrating synthetic lethality with drugs that are commonly used to limit DNA replication through dNTP pool depletion via inhibition of thymidylate synthetase and dihydrofolate reductase. Additionally, NEIL1-associated synthetic lethality has been achieved in combination with Fanconi anemia, group G. As a prelude to the development of strategies to exploit the potential benefits of DNA glycosylase inhibition, it was necessary to develop a reliable high-throughput screening protocol for this class of enzymes. Using NEIL1 as the proof-of-principle glycosylase, a fluorescence-based assay was developed that utilizes incision of site-specifically modified oligodeoxynucleotides to detect enzymatic activity. This assay was miniaturized to a 1536-well format and used to screen small molecule libraries for inhibitors of the combined glycosylase/AP lyase activities. Among the top hits of these screens were several purine analogs, whose postulated presence in the active site of NEIL1 was consistent with the paradigm of NEIL1 recognition and excision of damaged purines. Although a subset of these small molecules could inhibit other DNA glycosylases that excise oxidatively-induced DNA adducts, they could not inhibit a pyrimidine dimer-specific glycosylase.

Citation: Jacobs AC, Calkins MJ, Jadhav A, Dorjsuren D, Maloney D, et al. (2013) Inhibition of DNA Glycosylases via Small Molecule Purine Analogs. PLoS ONE 8(12): e81667. doi:10.1371/journal.pone.0081667

Editor: Michael R. Volkert, University of Massachusetts Medical School, United States of America

Received June 25, 2013; Accepted October 16, 2013; Published December 9, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This work was supported in part by National Institutes of Health (R01 DK75974, P01 CA160032) to RSL. ACJ was supported by National Institutes of Health under award number T32 ES007060. Research reported in this publication was also partially supported by the National Cancer Institute of the National Institutes of Health under award number T32CA106195 for MC. Support by the intramural research program of the National Center for Advancing Translational Sciences and the Molecular Libraries Initiative of the National Institutes of Health Roadmap for Medical Research (U54MH084681) is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lloydst@ohsu.edu

Introduction
The DNA base excision repair (BER) pathway has evolved to respond to ongoing challenges to genome stability that are posed by oxidation, alklylation, and deamination of DNA bases. In humans, the initiation of BER of DNA damage arising from oxidative stress occurs through the collective activities of the DNA glycosylases NEIL1, NEIL2, NEIL3, OGG1, and NTH1 (reviewed in [1]). Through a series of sequential biochemical steps, these enzymes flip the damaged nucleotide to an extrahelical position and catalyze removal of the damaged base through glycosyl bond scission, followed by phosphodiester bond breakage.

The various oxidatively induced DNA lesions, NEIL1 has distinct substrate preference for ring-fragmented purine derivatives such as 4,6-diamino-5-formamidopyrimidine (FapyAde) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyGua), and for a subset of ring-saturated pyrimidines, including thymine glycol (Tg) [2,3,4,5,6,7]. It also removes oxidation products of 7,8-dihydro-8-oxo-guanine (8-oxo-Gua), such as spiroidihydanitoin (Sp) and guanidinohydanitoin (Gh) from oligodeoxynucleotides [3]. OGG1 primarily recognizes 8-oxo-Gua and FapyGua [7], while together, NTH1 and NEIL2 remove the majority of ring-saturated pyrimidines [8,9]. Similar to NEIL1, NEIL3 is also specific for FapyAde and FapyGua, along with 8-hydroxyadenine and some pyrimidine-derived lesions such as Tg, 5-hydroxycytosine and 5-hydroxy-3-methylhydanitoin [10].

Although BER is critical for genome stability, there are circumstances in which the inhibition of this repair pathway as part of a synthetic lethality strategy has proven to be efficacious in the treatment of certain cancers. This therapeutic approach has been used effectively in treating BRCA1/2- or PTEN-deficient tumors (defective in homologous recombination) with inhibitors of PARP1, another key enzyme in the BER pathway [11,12,13,14]. In order to further identify and exploit other points in the BER pathway, Taricani et al [15] conducted an investigation to identify gene-specific pathways that would function as synthetic lethal partners with DNA glycosylases as the target for combination chemotherapy, and chemotherapeutic agents that function through depletion of cellular dNTP pools. Specifically, a key enzyme in thymidylate biosynthesis is thymidylate synthetase (TS),
which is responsible for the reductive methylation of dUMP by N5, N10-methylene tetrahydrofolate to form dTMP and dihydrofolate [16,17]. Drug inhibitors that target the TS pathway are widely used in the treatment of a variety of human cancers including ovarian, gastric, colorectal, pancreatic, breast, and head and neck. These are generally folate-based analogs, but nucleotide-based inhibitors are also used [18,19,20,21]. Due to their targets of action, these inhibitors are primarily toxic in the S-phase of the cell cycle through the depletion of intracellular dTTP, stalling of DNA replication and increasing dUMP incorporation into DNA. Commonly used inhibitors of TS are raltitrexed (Tomudex ®), RTX and nolatrexed (NOL), while inhibitors of dihydrofolate reductase (DHF) that result in depletion of tetrahydrofolate, with associated decreases in purine and pyrimidine synthesis, include methotrexate (MTX) and aminopterin (AMT). Taricani et al showed that although siRNA-mediated reduction in several DNA glycosylases in an osteosarcoma cell line, including NEIL1 and OGG1 [and to a lesser degree NTH1, MPG, SMUG1, and TDG] had no effect on cytotoxicity, when used in combination with minimally toxic doses of MTX, AMT, RTX and NOL, these combinations resulted in synergistic increases in γH2AX positive cells [15]. For NEIL1-depleted cells, treatments of MTX, AMT, RTX and NOL resulted in increased cytotoxicity of 10-fold, 7-fold, 9-fold and 5-fold, respectively. In addition, loss of NEIL1 function has also been shown to be synthetically lethal with the disruption of the Fanconi anemia DNA repair pathway, in which the disease is characterized by a deficiency in repair and tolerance of interstrand DNA cross-links [22]. To discover genes that may exhibit synthetic lethality with FanCγ, cells that were deficient in this gene were screened by various siRNA treatments [22]. In addition to the discovery of synthetic lethality with ATM, knockdown of Neil1 message also conferred lethality to FanCγ cells.

Based on these discoveries, we have developed a research strategy to discover inhibitors of DNA glycosylases, with an ultimate goal being to develop and utilize high affinity, high specificity small molecules in combination protocols to synergistically enhance the therapeutic efficacy of other cancer treatments, including, but not limited to TS and DHFR inhibitors. As a proof-of-principle, we have chosen to implement the first phase of these investigations by screening for small molecule inhibitors of NEIL1.

Strategies that create synthetic lethal relationships between disparate pathways have the potential to be far less toxic and debilitating to cancer patients, while still achieving a high therapeutic outcome. Together, these possible applications indicate the value of clinical exploitation of inhibitors of DNA glycosylases.

Materials and Methods

Reagents

Tri-HCl, Tween-20, EDTA, NaCl, KCl, MgCl₂, and DTT were purchased from Sigma-Aldrich (St. Louis, MO). Dimethyl sulfoxide (DMSO), urca, acrylamide, bisacrylamide and bovine serum albumin (BSA) were purchased from Fisher Scientific (Pittsburgh, PA). Black 384-well and 1,536-well plates were purchased from Corning (Corning, NY). DNA ladder was purchased from New England BioLabs (Ipswich, MA). 4,6-Diamino-5-formamidopyrimidine-13C, 15N₂ (FapyAde-13C, 15N₂) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine-13C, 15N₂ (FapyGua-13C, 15N₂) were purchased from Cambridge Isotope Laboratories (Andover, MA). Diamino-5-formamidopyrimidine-13C, 15N₂ (FapyAde-13C, 15N₂) were purchased from New England BioLabs (Ipswich, MA). 4,6-serum albumin (BSA) were purchased from Fisher Scientific were purchased from Sigma-Aldrich (St. Louis, MO). Dimethyl

Small molecule inhibitors

The screening collection consisted of the LOPAC12,000 collection from Sigma-Aldrich (1280 compounds) and cherry-picked purine analogs from the ~400,000-member Molecular Libraries Small Molecule Repository (MLSMR) collection. Additional hit compounds were purchased from Sigma-Aldrich.

Glycosylase enzymes

FPG and UDG were purchased from New England BioLabs. Human NEIL1 was expressed and purified as previously reported [4]. Human OGG1 and NTH1 expression constructs were generous gifts of Dr. Gregory Verdine (Harvard University, Cambridge, MA) and Dr. Susan Wallace (University of Vermont, Burlington, VT), respectively. His-tagged OGG1 and NTH1 proteins were expressed and purified using the same methods as described for NEIL1 [4]. T4 pyrimidine dimer DNA glycosylase (T4-pdg) was purified as previously described [23].

Oligodeoxynucleotide substrates

Oligodeoxynucleotides were purchased from Biosearch Technologies, Inc. (Novato, CA), Integrated DNA Technologies (Coralville, IA) or generously provided by Dr. Carmelo J. Rizzo (Department of Chemistry, Vanderbilt University, Nashville, TN). The double-stranded DNA substrate used in the fluorogenic assay was prepared from two oligodeoxynucleotides: the quencher (Black Hole Quencher 2 [BHQ-2]) strand, and fluorescent reporter (Tamra) strand (Figure 1). 8-oxo-Gua, Tg, and 2′-deoxyuridinid (dU) were incorporated synthetically, while Sp and Gh, were obtained through a secondary oxidation as previously reported [24]. Briefly, a 500 μL solution of the oligodeoxynucleotide containing 8-oxo-Gua (12 μM) in PBS (pH 7.2) was treated with NaIrCl₂ (100 μM) at 65°C for 30 min, then quenched with EDTA (160 μM) and purified by centrifugal filtration. DNA containing a site-specific abasic (AP) lesion was created by treating fully duplex DNA containing a site-specific uracil with UDG. Annealing of the oligodeoxynucleotide components was performed in 20 mM Tris-HCl, pH 8.0, 100 mM KCl by first incubating 1.5 molar equivalents of the quencher strand with one molar equivalent of the reporter fluorescent strand at 95°C for 5 min, followed by gradual cooling to room temperature. The choice of placing a T opposite the Sp/Gh site was made based on the most efficient kinetic data as reported by the David laboratory [25]. The double-stranded substrate was stored at 4°C until use.

Combined glycosylase/AP lyase cleavage assays

The 384-well fluorogenic assay was carried out in a 20 μL reaction mixture in 20 mM Tris·HCl pH 8.0, 100 mM KCl, and 0.1% BSA, with 5 nM active enzyme and 50 nM substrate. Possible inhibitors were incubated with the enzyme for at least 5 min at room temperature in a black, low-volume 384-well plate before addition of an equal volume of substrate to start the

5′-TAMRA-TCA CCX TCG TAC GAC TC 3′-BHQ2-2-AGT GGN AGC ATG CTG AG

| Substrate for TAMRA Strand | Quencher Strand |
|----------------------------|-----------------|
| NEIL1 | X = Sp/GH | N = T |
| Lyase (AP) | X = dU | N = T |
| OGG1 or FPG | X = 8-oxo-Gua | N = C |
| NTH1 or NEIL1 | X = Tg | N = A |

**Figure 1. Design of oligonucleotide substrates.**

doi:10.1371/journal.pone.0081667.g001
reaction. The plates were spun for 30 s at 1000 rcf to remove bubbles. The reactions were incubated at 37°C and fluorescence data collected on an Infinite M200 (Tecan, Mannefiel, Switzerland) equipped with standard optics (excitation filter 325 nm, and emission filter 580 nm). For the gel-based assay, reactions were initiated as described for the fluorogenic assay, but quenched with 20 μL 95% formamide at 20 min. The products were separated by electrophoresis through a 15% polyacrylamide gel containing 0 M urea and visualized by a Typhoon scanner (GE Life Sciences, Piscataway, NJ). The fraction of cleaved product was measured using ImageQuant software and analyzed using GraphPad Prism 6.

T4-pdg activity was assayed by a plasmid nicking assay with minor modifications of a previously described method [26,27]. Supercoiled pBR322 plasmid was irradiated with 254 nm ultraviolet (UV) light (100 μW/cm²) for 90 sec to produce approximately 10 thymine dimers per plasmid molecule [28]. Irradiated plasmid (10 nM) was then incubated in the presence or absence of inhibitors with 130 pM active T4-pdg, as assessed by NaCNBH4 trapping [27]. Reactions were started by addition of DNA substrate (75 nM final concentration) was added to start the reaction. The plate was immediately transferred into the ViewLux land) equipped with standard optics (excitation filter 525 nm, and emission filter 598 nm). For the gel-based assay, reactions were incubated at 37°C for 1 h and then centrifuged with 14,000 g for 20 min at 4°C. The supernatant fractions were separated and ethanol removed in a SpeedVac under vacuum. The samples were then frozen in liquid nitrogen and lyophilized overnight. To fully remove DMSO that would interfere with GC-MS/MS analysis, 500 μL water were added to the samples followed by lyophilization overnight. This procedure was repeated twice. Dried samples were derivatized and analyzed by GC-MS/MS as described [29,30]. For each data point, three independently prepared samples were used.

Intercalation assay
To test whether potential inhibitors could exert their inhibitory effect via DNA intercalation, 10 μL reactions containing 500 ng of a 100-bp DNA ladder were incubated at room temperature for 20 min with 40 μM of the selected compound. Ellipticine, a compound that is known to intercalate into duplex DNA was used as a control compound at a final concentration of 40 μM. Samples were resolved on a 1% agarose gel in 0.5X Tris-borate EDTA running buffer at 120 V for 2 h. Shifts in gel mobility were visualized by post staining with ethidium bromide and images were captured on a ChemiImager 5500 (Alpha Innotech, Santa Clara, CA) gel documentation system and densitometry was performed using Image J software. Percent remaining form I DNA was calculated by applying a factor of 1.42 to the form I band intensity and then dividing form I by the sum of form I, II and III. The number of nicks per molecule were estimated based on a Poisson distribution, in which nicks per molecule = -ln (mass fraction of form I DNA remaining), and inhibition of activity was measured as the percentage reduction in the number of nicks per plasmid molecule compared to reactions without inhibitor.

High-throughput screen in 1536-well format
The fluorogenic assay was miniaturized to 4 μL in 1536-well black solid plates by optimization of the enzyme and Sp/Gh substrate concentrations. Briefly, 3 μL of 25 nM NEIL1 were dispensed into each well of a 1536-well plate (except buffer in 1536-well plate) and then 1 μL of the Sp/Gh-containing DNA substrate (75 nM final concentration) was added to start the reaction. The plate was immediately transferred into the ViewLux reader for the kinetic fluorescence read. Initial rate data were normalized against uninhibited and no-enzyme controls and the resulting percent activities as a function of compound concentration were fitted using the Hill equation.

Cell survival assay
Wild-type or Neil1-KO MEFs were plated in a 96-well opaque walled dish (2000 cells/well) and incubated for 18 h to allow for attachment. Inhibitor (80 μL) diluted in DMEM was added to the cells at various concentrations ranging from 0–20 μM, and incubated for an additional 72 h. Cell viability was measured using the CellTitier Glo reagent (Promega, Madison, WI) and was prepared as per the manufacturer’s instructions, with 50 μL of the reconstituted reagent added to each well. Cells were incubated for 10 min on an orbital shaker to induce cell lysis. Survival was measured by luminescence on a microplate reader (TECAN) and normalized to no-treatment control.

Measurement of the activity of NEIL1 by gas chromatography/tandem mass spectrometry
The enzymatic activity of NEIL1 was measured using gas chromatography/isotope-dilution tandem mass spectrometry (GC-MS/MS) and calf thymus DNA samples γ-irradiated at 20 Gy as described [29,30]. Aliquots of FapyAde-13C,15N2 and Fapy-Gua-13C,15N2 were added as internal standards to 50 μg of DNA samples. After drying in a SpeedVac, DNA samples were dissolved in 50 μL of an incubation buffer consisting of 50 mM phosphate buffer (pH 7.4), 100 mM KCl, 1 mM EDTA, and 0.1 mM dithiothreitol, and then incubated with 2 μg NEIL1 for 1 h at 37°C without any inhibitor, DMSO alone, or with 10 μL of an inhibitor solution in DMSO (2 mM). After incubation, 150 μL of cold ethanol was added. The samples were kept at −20°C for 1 h and then centrifuged with 14,000 g for 30 min at 4°C. The supernatant fractions were separated and ethanol removed in a SpeedVac under vacuum. The samples were then frozen in liquid nitrogen and lyophilized overnight. To fully remove DMSO that would interfere with GC-MS/MS analysis, 500 μL water were added to the samples followed by lyophilization overnight. This procedure was repeated twice. Dried samples were derivatized and analyzed by GC-MS/MS as described [29,30]. For each data point, three independently prepared samples were used.

Results and Discussion
Development of a high-throughput assay for combined DNA glycosylase/AP lyase activities
The overall design of a high-throughput, fluorescence-based assay to detect small molecule inhibitors of DNA glycosylases that have an associated AP lyase activity was patterned after an assay previously developed for the detection of inhibitors of apurinic/apyrimidinic endonuclease 1 (APE1) [31] and is also similar in principle to assays designed to detect inhibitors of DNA polymerases [32,33]. This basic strategy contrasts with the uracil-directed, tethered ligand strategy developed by the Sivers group for discovery of UDG2 inhibitors [34], or the hairpin strategy utilized by the Iwai group for probing cellular BER activity [35]. While these models were efficient in the identification of novel inhibitors [36,37] and allowed for detection of glycosylase activity, neither approach was designed or adapted to probe large libraries of small molecules as part of a high-throughput screen.

To create a screening assay for inhibitors that can be generalized to most DNA glycosylases, we chose to reduce this to practice using NEIL1, an enzyme which possesses both glycosylase and AP lyase activities. Although the specificities of DNA glycosylases are dictated by the range of DNA base damages that can be recognized and removed by cleavage of the respective
glycosyl bond, this incision does not result in sufficient DNA structural changes that can be detected by changes in fluorescence. The assay that was developed exploits the lyase step which follows glycosidic bond cleavage in the bifunctional DNA glycosylases and results in strand cleavage that can be detected via lowering of the melting temperature of the fluorescent-containing DNA molecule (Figure 2). In principle, this assay can be modified for any glycosylase that has an associated AP lyase activity, using appropriately designed DNA substrates. Briefly, in this assay, a short synthetic oligodeoxynucleotide containing a site-specific lesion (70:30 mixture of SpGh adducts) and a 5'-TAMRA fluorophore was hybridized to a complementary DNA containing a 3'-BHQ-2 molecule. After annealing the strands, the TAMRA and the BHQ-2 were spatially adjacent. Although this duplex produced only background levels of fluorescence, following addition of a bifunctional glycosylase, cleavage at the site of the lesion reduced the melting temperature of the fluorescently-labeled fragment. The incised DNA fragment containing the TAMRA diffused into bulk solution and its fluorescent signal was detected.

In contrast, addition of small molecule inhibitors of the glycosylase would prevent incision such that no fluorescent signal would be produced and the solution would remain dark (Figure 2).

Specifically for NEIL1, a 17-mer oligodeoxynucleotide containing an 8-oxo-Gua lesion positioned 6 nucleotides downstream of a 5'-TAMRA fluorophore was subjected to oxidation to produce DNAs containing both Sp and Gh, two modified nucleotides that have been previously established to be excellent substrates for NEIL1 [24]. HPLC analyses of the products revealed that the secondary oxidation reaction had proceeded to completion, producing a mixture (70:30 ratio) of Sp and Gh. The lesion strand was hybridized to a complementary DNA containing a 3'-BHQ-2 [38]. Incubation of this substrate with NEIL1, but not OGG1, resulted in the incision of the substrate DNA. These data verified that the fluorescently-labeled DNA was an appropriate substrate for NEIL1 (Figure 3).

As an initial reduction-to-practice, experiments were optimized using a 384-well platform, with a final total reaction volume of 20 μL, in which varying concentrations of NEIL1 were added to solutions of lesion-containing substrate DNA. After mixing, plates were transferred to a plate reader and fluorescence data collected by monitoring emission at 598 nm throughout a 20 min reaction (Figure 4A). These data revealed an enzyme-dependent increase in fluorescence intensity was a measure of DNA incision by monitoring emission at 598 nm throughout a 20 min reaction were transferred to a plate reader and fluorescence data collected. The results of this screen yielded 42 potential inhibitors with IC50 values in the range of 5–50 μM (Figure S1). For triaging purposes, these compounds were rescreened using the 384-well format and a subset of these were subsequently confirmed by incision of oligodeoxynucleotides containing site-specific base lesions as analyzed by mobility differences through polyacrylamide gels. In addition to CGP-74514A, a total of four more compounds (P2 NCGC00188618, P6 NCGC000188616, P7 NCGC000188617 and P8 NCGC000188619) displayed favorable IC50 values, as well as an evaluation of the shape of the response curves. In addition to the anticipated inhibitors (known DNA intercalators, such as ellipticine [IC50 = 2 μM]) and other small molecules that have been previously established to be promiscuous inhibitors (such as aurintricarboxylic acid [IC50 < 1 μM]), one interesting hit from this screen was CGP-74514A (NCGC ID is NCGC00015229) (Figure 5A). CGP-74514A is a known small molecule inhibitor of Cdk1 in which the structure of this molecule is based on a purine ring backbone.

Since the preferred targets of NEIL1 are modified purines, inhibition by CGP-74514A suggested that other purines may also have inhibitory properties. An additional library consisting of ~1400 modified purine analogs was cherry-picked from other NCGC collections and screened over a 5 concentration range. The results of this screen yielded 42 potential inhibitors with IC50 values in the range of 5–50 μM (Figure S1). For triaging purposes, these compounds were rescreened using the 384-well format and a subset of these were subsequently confirmed by incision of oligodeoxynucleotides containing site-specific base lesions as analyzed by mobility differences through polyacrylamide gels. In addition to CGP-74514A, a total of four more compounds (P2 NCGC00188618, P6 NCGC000188616, P7 NCGC000188617 and P8 NCGC000188619) displayed favorable IC50 values, as well as an evaluation of the shape of the response curves. In addition to the anticipated inhibitors (known DNA intercalators, such as ellipticine [IC50 = 2 μM]) and other small molecules that have been previously established to be promiscuous inhibitors (such as aurintricarboxylic acid [IC50 < 1 μM]), one interesting hit from this screen was CGP-74514A (NCGC ID is NCGC00015229) (Figure 5A). CGP-74514A is a known small molecule inhibitor of Cdk1 in which the structure of this molecule is based on a purine ring backbone.

Since the preferred targets of NEIL1 are modified purines, inhibition by CGP-74514A suggested that other purines may also have inhibitory properties. An additional library consisting of ~1400 modified purine analogs was cherry-picked from other NCGC collections and screened over a 5 concentration range. The results of this screen yielded 42 potential inhibitors with IC50 values in the range of 5–50 μM (Figure S1). For triaging purposes, these compounds were rescreened using the 384-well format and a subset of these were subsequently confirmed by incision of oligodeoxynucleotides containing site-specific base lesions as analyzed by mobility differences through polyacrylamide gels. In addition to CGP-74514A, a total of four more compounds (P2 NCGC00188618, P6 NCGC000188616, P7 NCGC000188617 and P8 NCGC000188619) displayed favorable IC50 values, as well as an evaluation of the shape of the response curves. In addition to the anticipated inhibitors (known DNA intercalators, such as ellipticine [IC50 = 2 μM]) and other small molecules that have been previously established to be promiscuous inhibitors (such as aurintricarboxylic acid [IC50 < 1 μM]), one interesting hit from this screen was CGP-74514A (NCGC ID is NCGC00015229) (Figure 5A). CGP-74514A is a known small molecule inhibitor of Cdk1 in which the structure of this molecule is based on a purine ring backbone.

Since the preferred targets of NEIL1 are modified purines, inhibition by CGP-74514A suggested that other purines may also have inhibitory properties. An additional library consisting of ~1400 modified purine analogs was cherry-picked from other NCGC collections and screened over a 5 concentration range. The results of this screen yielded 42 potential inhibitors with IC50 values in the range of 5–50 μM (Figure S1). For triaging purposes, these compounds were rescreened using the 384-well format and a subset of these were subsequently confirmed by incision of oligodeoxynucleotides containing site-specific base lesions as analyzed by mobility differences through polyacrylamide gels. In addition to CGP-74514A, a total of four more compounds (P2 NCGC00188618, P6 NCGC000188616, P7 NCGC000188617 and P8 NCGC000188619) displayed favorable IC50 values, as well as an evaluation of the shape of the response curves. In addition to the anticipated inhibitors (known DNA intercalators, such as ellipticine [IC50 = 2 μM]) and other small molecules that have been previously established to be promiscuous inhibitors (such as aurintricarboxylic acid [IC50 < 1 μM]), one interesting hit from this screen was CGP-74514A (NCGC ID is NCGC00015229) (Figure 5A). CGP-74514A is a known small molecule inhibitor of Cdk1 in which the structure of this molecule is based on a purine ring backbone.

Since the preferred targets of NEIL1 are modified purines, inhibition by CGP-74514A suggested that other purines may also have inhibitory properties. An additional library consisting of ~1400 modified purine analogs was cherry-picked from other NCGC collections and screened over a 5 concentration range. The results of this screen yielded 42 potential inhibitors with IC50 values in the range of 5–50 μM (Figure S1). For triaging purposes, these compounds were rescreened using the 384-well format and a subset of these were subsequently confirmed by incision of oligodeoxynucleotides containing site-specific base lesions as analyzed by mobility differences through polyacrylamide gels. In addition to CGP-74514A, a total of four more compounds (P2 NCGC00188618, P6 NCGC000188616, P7 NCGC000188617 and P8 NCGC000188619) displayed favorable IC50 values, as well as an evaluation of the shape of the response curves. In addition to the anticipated inhibitors (known DNA intercalators, such as ellipticine [IC50 = 2 μM]) and other small molecules that have been previously established to be promiscuous inhibitors (such as aurintricarboxylic acid [IC50 < 1 μM]), one interesting hit from this screen was CGP-74514A (NCGC ID is NCGC00015229) (Figure 5A). CGP-74514A is a known small molecule inhibitor of Cdk1 in which the structure of this molecule is based on a purine ring backbone.

Since the preferred targets of NEIL1 are modified purines, inhibition by CGP-74514A suggested that other purines may also have inhibitory properties. An additional library consisting of ~1400 modified purine analogs was cherry-picked from other NCGC collections and screened over a 5 concentration range. The results of this screen yielded 42 potential inhibitors with IC50 values in the range of 5–50 μM (Figure S1). For triaging purposes, these compounds were rescreened using the 384-well format and a subset of these were subsequently confirmed by incision of oligodeoxynucleotides containing site-specific base lesions as analyzed by mobility differences through polyacrylamide gels. In addition to CGP-74514A, a total of four more compounds (P2 NCGC00188618, P6 NCGC000188616, P7 NCGC000188617 and P8 NCGC000188619) displayed favorable IC50 values, as well as an evaluation of the shape of the response curves. In addition to the anticipated inhibitors (known DNA intercalators, such as ellipticine [IC50 = 2 μM]) and other small molecules that have been previously established to be promiscuous inhibitors (such as aurintricarboxylic acid [IC50 < 1 μM]), one interesting hit from this screen was CGP-74514A (NCGC ID is NCGC00015229) (Figure 5A). CGP-74514A is a known small molecule inhibitor of Cdk1 in which the structure of this molecule is based on a purine ring backbone.
fluorescent-based kinetic inhibition analyses. Two additional purine analogs that were poor inhibitors in the HTS (P11 NCGC ID = NCGC000182914 and P19 NCGC ID = MLS001126460) were also re-analyzed and shown to have IC_{50} above 50 μM (data not shown). Single concentration (10 μM purine analog) kinetic analyses showed significant inhibition and 7 concentration inhibition curves revealed IC_{50}s between 5–14 μM (Figure 7).

Inhibition of NEIL1 activity on γ-irradiated DNA as measured by GC-MS/MS

Although Gh and Sp are excellent substrates for NEIL1, these are likely not to be the biologically relevant substrates. Thus, to determine if the compounds that were identified above were effective in the inhibition of NEIL1 against its biologically relevant substrates FapyAde and FapyGua [5,6], γ-irradiated calf thymus DNA was used as a substrate. The excision by NEIL1 of these substrates from DNA was measured by GC-MS/MS with isotope-
dilution. Figure 8 illustrates the excision of FapyAde and FapyGua by NEIL1 from γ-irradiated calf thymus DNA in the absence or presence of inhibitors. NEIL1 exhibited strong activity for excision of both lesions in agreement with previously published data [2,3,4,5,6]. Inhibitors P2, P6, P7 and P8 significantly reduced the activity of NEIL1 ($p<0.005$). Some inhibition by DMSO alone was also observed when compared with excision by NEIL1 alone ($p = 0.01$). However, when compared to DMSO, the inhibitions by P2, P6, P7 and P8 were highly significant ($p<0.005$). To a lesser extent, P11 (NCGC ID = NCGC000182914) inhibited FapyAde excision ($p = 0.0046$); but not FapyGua excision ($p = 0.08$). These data suggest that the observed inhibition of FapyAde excision by P11 may have been the effect of DMSO, not the inhibitor itself. Inhibitor P19 exhibited no inhibition. Statistical analyses of these data were performed using the GraphPad Prism 5.04 software (La Jolla, CA, USA) and two-tailed nonparametric Mann Whitney test with Gaussian approximation and confidence interval of 95%. A $p$-value $<0.05$ was assumed to correspond to statistical significance.

Purine analog inhibitors of NEIL1 inhibit other glycosylases involved in the recognition of other oxidatively-induced DNA damage

In humans, several glycosylases, including OGG1, NTH1, NEIL2, and NEIL3 may participate in the removal of a wide variety of oxidized bases. Thus, although several of the purine analogs inhibited the ability of NEIL1 to remove Sp, Gh, FapyAde and FapyGua lesions, these assays were not informative concerning their specificity for NEIL1 and did not address whether these molecules could inhibit other DNA glycosylase/AP lyases that participate in the removal of oxidatively-induced DNA lesions. To address this question, assays were designed to measure inhibition of OGG1 and NTH1, as well as the *Escherichia coli* glycosylase-AP lyase, FPG. In order to compare the relative efficiencies of inhibition between NEIL1 and these other glycosylase/AP lyases, it was necessary to identify common DNA substrates and pair-wise analyze inhibition data. To compare inhibition of NEIL1 versus NTH1, oligodeoxynucleotides were synthesized that contained a site-specific thymine glycol (TG) adduct, while comparative inhibition data for OGG1 and FPG were collected using an oligodeoxynucleotide containing a site-specific 8-oxo-Gua. In control reactions (no inhibitor added), each enzyme generated the expected incised products, confirming the validity of the assay. Since compounds P2, P6, P7, and P8 showed significant inhibition of NEIL1 activity on Sp/Gh during the HTS, they were used to determine the IC_{50} values of purine inhibitors toward each of the base excision repair glycosylases (Figure 9). IC_{50} values ranged from 5–50 μM, with FPG and NEIL1 being the most severely inhibited for all the compounds tested. Specifically, using the same 8-oxo-Gua substrate, this series of compounds elicited a 2–5 fold more potent IC_{50} when used to inhibit FPG relative to OGG1. In

![Figure 5. High-throughput screen of selected small molecule libraries. A) Inhibition of NEIL1 activity in the HTS of the LOPAC library by aurintricarboxylic acid (squares), ellipticine (triangles), and CGP-74514A (circles). B) Inhibition of NEIL1 activity by purine analogs P2 (circles), P6 (squares), P7 (triangles), and P8 (inverted triangles). doi:10.1371/journal.pone.0081667.g005](image)

![Figure 6. Purine analogs that inhibit NEIL1. doi:10.1371/journal.pone.0081667.g006](image)
general, P8 showed the poorest inhibition for all enzymes except for NTH1. Furthermore, although not always the most potent inhibitor, P6 appears to be the most general inhibitor, with the IC$_{50}$ values for all four enzymes ranging between 9 mM and 28 mM. Additionally, experiments were designed to test whether compounds P2, P6, P7, and P8 could inhibit a pyrimidine dimer-specific glycosylase/AP lyase, T4 pyrimidine dimer DNA glycosylase (T4-pdg) that also has an associated AP lyase activity, using an UV-irradiated plasmid nicking assay. T4-pdg was preincubated with the highest concentration of each inhibitor (40 mM) and subsequently incubated for 15 min with plasmid DNAs containing ~10 dimers per molecule. Following triplicate independent analyses by agarose gel electrophoresis, analyses of the extent of nicking revealed that P2, P6, P7, and P8 inhibited activity by <1%, 32%, 13%, and 14%, respectively. Since it was not possible to increase these concentrations significantly higher to

Figure 7. Inhibition of NEIL1 activity with 10 μM concentrations of select compounds. A) CGP-74514A, B) P2, C) P6, D) P7, E) P8 compared to no inhibitor (gray squares) or no enzyme (gray triangles). F) IC$_{50}$ values determined during validation of HTS.
doi:10.1371/journal.pone.0081667.g007

Figure 8. Determination of NEIL1 inhibition by GS-MS/MS. Levels of A) FapyGua and B) FapyAde released from γ-irradiated DNA by NEIL1 in the absence or presence of various inhibitors.
doi:10.1371/journal.pone.0081667.g008

Inhibitors of DNA Glycosylases
Specificity of the inhibition of NEIL1

Given that several of the purine analogs inhibited selected DNA glycosylases, there are several possible mechanisms by which these small molecules could inhibit strand scission. Theoretically, it could bind in the active site or at an allosteric site and prevent the cleavage of the lesion’s glycosidic bond, or alternatively, it may allow glycosidic bond cleavage, producing an abasic site, but inhibit the lyase activity. Alternatively, it could interact with the DNA in such a way that the enzyme either does not bind or is unable to locate and cleave at the site of the lesion.

To test for inhibition of lyase activity, the DNA substrate was changed to an oligodeoxynucleotide containing an AP site. In the absence of inhibitor molecules, this substrate reacted rapidly with NEIL1, NTH1, OGG1 or FPG to generate either a β or a β/δ elimination product. Although the IC₅₀ values for these reactions were higher than that measured for the glycosylation reaction, in general, the addition of the purine inhibitors resulted in a significant reduction in the cleavage reaction (Figure 10A). The major exception to this was observed for OGG1, in which it showed very little lyase inhibition with all compounds except P6. This could be potentially explained by P2, P7, and P8 not interfering with OGG1’s catalytic residues Lys249 or Asp268, but rather the Lys249-Gly253 dipole that recognizes the lesion [39], producing a lyase-only activity similar to a C253A mutant [40].

Overall, these data suggest that these purine analogs preferentially act to block the glycosylation, and to a lesser extent, the lyase step. This fits with the hypothesis that purine analogs would fit inside the active site of these glycosylases, sterically hindering the residues required for activity.

To assay whether these inhibitors could block NEIL1 activity through DNA intercalation, a DNA ladder gel-shift assay was performed, with ellipticine serving as a positive control [33]. A duplex DNA ladder was incubated with each inhibitor, and analyzed for electrophoretic mobility shift. As shown in Figure 10B, while ellipticine showed a major reduction in the electrophoretic mobility of the DNA ladder, none of the purine analog inhibitors produced such a shift. These data indicate that the inhibitors had minimal, if any interaction with the DNA, and instead produced their effect through interaction with the enzymes. These data are also consistent with the mass spectrometry data in which there are vast excesses of undamaged DNAs present in these reactions.

Cytotoxicity of purine analogs

Although the overall goal of this investigation was to design and reduce-to-practice a reliable, high-throughput fluorescence-based screening assay for inhibitors of DNA glycosylases, it was also of interest to determine if these compounds exhibited cellular toxicities that would be indicative of cellular uptake and interference with critical cellular functions. To experimentally address this question, mouse embryo fibroblasts from wild-type and Neil1 knockout mice were treated with increasing concentrations of P2, P6, P7, and P8. Cell survival was measured after a 72 h exposure. For all four compounds, the 37% survival was greater in the Neil1 knockout cells relative to the wild-type. The D₅₀ ratios for WT:Neil1 were as follows: P2: 6:10 μM; P6: 5.8 μM; P7: 12:15 μM; and P8: 7:11 μM, respectively. The trend of these data are generally consistent with the relative IC₅₀ values for each of the compounds and the values are within 2-fold of the calculated IC₅₀ values for all four compounds tested. Although these data reveal that in the absence of cellular NEIL1, the relative cytotoxicities of these compounds is reduced, the mechanism(s) by which these purine analogs kill cells is unknown. In addition to modulating BER, there are potentially many other candidate enzymes that may be compromised by the introduction of these compounds, including but not limited to kinases, DNA and RNA polymerases, other DNA repair complexes or helicases. However, given that the concentrations of these compounds are several orders of magnitude higher than what would be considered as a pharmacologically-relevant dose, detailed mechanistic analyses of the current set of compounds is highly premature. Such studies and the development of appropriate cell culture and animal models will need to be generated concomitantly with the evolution of higher affinity, greater specificity molecules.

Conclusions

Overall, the data presented herein form the foundation for future drug discovery for the entire family of DNA glycosylases. Even though the current assay design relied on the strand incision activity following the cleavage of the glycosyl bond through β or β/δ elimination reactions, for DNA glycosylases that only cleave the glycosyl bond leaving an AP site, the assay could be readily modified to include a secondary biochemical or chemical reaction to cleave the phosphodiester backbone at that site. Thus, the small molecule inhibitors that were identified in this limited screen serve as a proof-of-concept for the initial phase of the drug discovery process. However, the molecules identified herein do not necessarily represent the only lead compounds for future medicinal chemistry development. This cautionary note is exemplified by the observation that while NEIL1 is primarily associated with recognition of damaged purines, NTH1 covers a broad spectrum of saturated pyrimidines, and both NEIL1 and NTH1 were similarly inhibited by many of these small molecules. Future experimental strategies will include the development of cell biology-based readouts for DNA glycosylase inhibitors and the screening of additional libraries for higher affinity inhibitors with greater specificity.
Figure 10. Specificity of the inhibition of NEIL1. A) Inhibition of the lyase activity of various bifunctional glycosylases with purine analogs. B) DNA ladder gel shift assay with addition of various inhibitors or ellipticine control. doi:10.1371/journal.pone.0081667.g010

Supporting Information

Figure S1 Compounds of interest from the HTS of a purine analog library. (PDF)

Acknowledgments

Certain commercial equipment or materials are identified in this paper in order to specify adequately the experimental procedure. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology, nor does it imply that the materials or equipment identified are necessarily the best available for the purpose.

Author Contributions

Conceived and designed the experiments: ACJ MC RSL AS MD. Performed the experiments: ACJ MC AJ DD DM PJ. Analyzed the data: ACJ MC AJ DD DM AS PJ MD AKM RSL. Contributed reagents/materials/analysis tools: RSL AKM AS MD. Wrote the paper: AJ MC RSL MD.

References

1. Sampath H, McCullough AK, Lloyd RS (2012) Regulation of DNA glycosylases and their role in limiting disease. Free Radic Res 46: 469-478.

2. Hazra TK, Inumi T, Boldogh I, Imhoff B, Kow YW, et al. (2002) Identification and characterization of a human DNA glycosylase for repair of modified bases in oxidatively damaged DNA. Proc Natl Acad Sci U S A 99: 3523-3527.

3. Jaruga P, Bircinsoglu M, Rosenquist TA, Dizdaroglu M (2004) Mouse NEIL1 protein is specific for excision of 2,6-diamino-4-hydroxy-5-formamidopyrimidine and 4,6-diamino-5-formamidopyrimidine from oxidatively damaged DNA. Biochemistry 43: 15099-15104.

4. Roy LM, Jaruga P, Wood TG, McCullough AK, Dizdaroglu M, et al. (2007) Human polymorphic variants of the NEIL1 DNA glycosylase. J Biol Chem 282: 15790-15798.

5. Chan MK, Ocampo-Hafalla MT, Vartanian V, Jaruga P, Kirkali G, et al. (2009) Targeted deletion of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence of novel carcinogenic oxidative damage to DNA. DNA Repair (Amst) 8: 786-794.

6. Jaruga P, Xiao Y, Vartanian V, Lloyd RS, Dizdaroglu M (2010) Evidence for the involvement of DNA repair enzyme NEIL1 in nucleotide excision repair of (5'R)- and (5'S)-8,5'-cyclo-2'-deoxyadenosines. Biochemistry 49: 1053-1055.

7. Dherin C, Radicella JP, Dizdaroglu M, Boiteux S (1999) Excision of oxidatively damaged DNA bases by the human alpha-hOgg1 protein and the polymorphic alpha-hOgg1Ser329Cys protein is frequently found in human populations. Nucl Acids Res 27: 4001-4007.

8. Dizdaroglu M, Bauche C, Rodriguez H, Lavial J (2000) Novel substrates of Escherichia coli nih protein and its kinetics for excision of modified bases from DNA damaged by free radicals. Biochemistry 39: 5596-5592.

9. Dizdaroglu M, Karahalil B, Senturker S, Buckley TJ, Roldan-Arjona T (1999) Excision of products of oxidative DNA base damage by human NTH1 protein. Biochemistry 38: 245-246.

10. Liu M, Bandaru V, Bond JP, Jaruga P, Zhao X, et al. (2010) The mouse ortholog of NEIL3 is a functional DNA glycosylase in vitro and in vivo. Proc Natl Acad Sci U S A 107: 4925-4930.

11. O’Brien T, Stokey D (2009) Converting cancer mutations into therapeutic opportunities. EMBO Mol Med 1: 297-299.

12. Kummars S, Chen A, Parchment RE, Kinders RJ, Ji J, et al. (2012) Advances in using PARP inhibitors to treat cancer. BMC Med 10: 25.

13. Mendez-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, et al. (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315-322.

14. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.

15. Taricani L, Shanahan F, Pierce RH, Guzi TJ, Parry D (2010) Phenotypic enhancement of thymidylate synthetase pathway inhibitors following ablation of NEIL1 DNA glycosylase/lyase. Cell Cycle 9: 4876-4883.

16. Carreras CW, Sauti DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64: 721-762.

17. Harrap KR, Jackman AL, Newell DR, Taylor GA, Hughes LR, et al. (1989) Thymidylate synthase: a target for anticaner drug design. Adv Enzyme Regul 29: 161-179.

18. FitzGerald GR, Wick MM (1987) Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma. J Invest Dermatol 88: 66-70.

19. McGuire JJ (2003) Anticancer anafolates: current status and future directions. Curr Pharm Des 9: 2593-2613.

20. Rose MG, Farrell MP, Schmitz JC (2002) Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer 1: 220-229.

21. Wilson PM, LaBonte M, Lenz HJ, Mack PC, Ladner RD (2012) Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer. Mol Cancer Ther 11: 616-628.

22. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, et al. (2007) Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117: 1440-1449.

23. Johnson JL, Lowell BC, Ryzhikina OP, Lloyd RS, McCullough AK (2011) TAT-mediated delivery of a DNA repair enzyme to skin cells rapidly initiates repair of UV-induced DNA damage. J Invest Dermatol 131: 753-761.

24. Zhao X, Muller JG, Halanych M, David SS, Burrows CJ (2007) In vitro ligation of oligodeoxynucleotides containing C8-oxidized purine bases using bacteriophage T4 DNA ligase. Biochemistry 46: 3734-3744.

25. Krishnamurthy N, Zhao X, Burrows CJ, David SS (2008) Superior removal of hydantoin lesions relative to other oxidized bases by the human DNA glycosylase hNEIL1. Biochemistry 47: 7137-7146.
26. Lloyd RS, Hanawalt PC, Dodson ML (1980) Processive action of T4 endonuclease V on ultraviolet-irradiated DNA. Nucleic Acids Res 8: 5113–5127.

27. McCullough AK, Romberg MT, Nyaga S, Wei Y, Wood TG, et al. (1998) Characterization of a novel cis-syn and trans-syn-II pyrimidine dimer glycosylase/AP lyase from a eukaryotic algal virus, Paramecium bursaria chlorella virus-1. J Biol Chem 273: 13136–13142.

28. Gruskin EA, Lloyd RS (1986) The DNA scanning mechanism of T4 endonuclease V: Effect of NaCl concentration on processive nicking activity. J Biol Chem 261: 9607–9613.

29. Jaruga P, Kirkali G, Dizdaroglu M (2008) Measurement of formamidopyrimidines in DNA. Free Radic Biol Med 45: 1601–1609.

30. Reddy PT, Jaruga P, Kirkali G, Tuna G, Nelson BC, et al. (2013) Identification and quantification of human DNA repair protein NEIL1 by liquid chromatography/isotope-dilution tandem mass spectrometry. J Proteome Res 12: 1049–1061.

31. Dorjsuren D, Kim D, Vyjayanti VN, Maloney DJ, Jadhav A, et al. (2012) Diverse small molecule inhibitors of human apurinic/apyrimidinic endonuclease APE1 identified from a screen of a large public collection. PLoS One 7: e47974.

32. Dorjsuren D, Wilson DM 3rd, Beard WA, McDonald JP, Austin CP, et al. (2009) A real-time fluorescence method for enzymatic characterization of specialized human DNA polymerases. Nucleic Acids Res 37: e128.

33. Yamanaka K, Dorjsuren D, Loef RL, Egli M, Maloney DJ, et al. (2012) A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase kappa. PLoS One 7: e45032.

34. Jiang YL, Krosky DJ, Seiple L, Sivers JT (2003) Uracil-directed ligand rebinding: an efficient strategy for uracil DNA glycosylase (UNG) inhibitor development. J Am Chem Soc 125: 17412–17420.

35. Matsumoto N, Toga T, Hayashi R, Sugasawa K, Katayanagi K, et al. (2010) Fluorescent probes for the analysis of DNA strand scission in base excision repair. Nucleic Acids Res 38: e101.

36. Jiang YL, Chang S, Krosky DJ, Sivers JT (2006) Synthesis and high-throughput evaluation of triskelion uracil libraries for inhibition of human dUTPase and UNG2. Bioorg Med Chem 14: 5666–5672.

37. Krosky DJ, Blanchet MA, Seiple L, Chung S, Amzel LM, et al. (2006) Mimicking damaged DNA with a small molecule inhibitor of human UNG2. Nucleic Acids Res 34: 5872–5879.

38. Simeonov A, Kulkarni A, Dorjsuren D, Jadhav A, Shen M, et al. (2009) Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS One 4: e5740.

39. Banerjee A, Yang W, Karpplus M, Verdiene GL (2005) Structure of a repair enzyme interrogating undamaged DNA elucidates recognition of damaged DNA. Nature 434: 612–618.

40. Dalhus B, Forsbring M, Helle IH, Viik ES, Forstrom RJ, et al. (2011) Separation-of-function mutants unravel the dual-reaction mode of human 8-oxoguanine DNA glycosylase. Structure 19: 117–127.